Get the Stockscreener App
14.20
0.64%
0.09
After Hours:
14.19
-0.010
-0.07%
Rocket Pharmaceuticals Inc stock is traded at $14.20, with a volume of 598.16K.
It is up +0.64% in the last 24 hours and down -16.67% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
See More
Previous Close:
$14.11
Open:
$14.26
24h Volume:
598.16K
Relative Volume:
0.68
Market Cap:
$1.28B
Revenue:
-
Net Income/Loss:
$-249.31M
P/E Ratio:
-4.29
EPS:
-3.31
Net Cash Flow:
$-209.70M
1W Performance:
+8.90%
1M Performance:
-16.67%
6M Performance:
-33.71%
1Y Performance:
-37.64%
1-Day Range:
$13.99
$14.52
1-Week Range:
$12.65
$15.01
52-Week Range:
$12.62
$32.52
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
14.20 | 1.28B | 0 | -249.31M | -209.70M | -3.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
3 Small-Cap Stocks That Are Ready to Rocket Higher - MarketBeat
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference - BioSpace
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock eyes $1B+ peak sales - Investing.com
(RCKT) Long Term Investment Analysis - Stock Traders Daily
Westfield Capital Management Co. LP Acquires 165,911 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 6.3%Time to Buy? - MarketBeat
Leerink Partnrs Has Strong Outlook for RCKT FY2025 Earnings - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Chardan Capital - Defense World
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline - TipRanks
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst - AOL
Leerink Partners Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $44.00 - MarketBeat
Rocket Pharmaceuticals' (RCKT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives Buy Rating from Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals shares hold strong with Buy rating By Investing.com - Investing.com UK
First Turn Management LLC Purchases 60,317 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharma reports promising Phase 1 results for Danon disease therapy - Investing.com Australia
Rocket Pharma Stock Slips Despite New Long-Term Data On Phase-I Study; Retail Sentiment Slides - Asianet Newsable
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals (RCKT) Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data - StreetInsider.com
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference - Business Wire
Rocket Pharmaceuticals is Now Oversold (RCKT) - Nasdaq
When (RCKT) Moves Investors should Listen - Stock Traders Daily
Chardan Capital Has Strong Estimate for RCKT FY2024 Earnings - MarketBeat
RCKT stock touches 52-week low at $15.96 amid market challenges - Investing.com India
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharma to Present Groundbreaking Danon Disease Gene Therapy Data at AHA 2024 | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus - Yahoo Finance
Privium Fund Management B.V. Has $5.45 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $51.75 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Rocke - GuruFocus.com
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference - BioSpace
Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - Yahoo Finance
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation - Yahoo Finance
Harbor Capital Advisors Inc. Has $3.11 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals executive sells $51,205 in common stock - Investing.com
Rocket Pharmaceuticals executive sells $51,205 in common stock By Investing.com - Investing.com UK
Long Term Trading Analysis for (RCKT) - Stock Traders Daily
(RCKT) Trading Report - Stock Traders Daily
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Kinnari | See Remarks |
Nov 21 '24 |
Sale |
13.05 |
4,588 |
59,892 |
392,395 |
| Shah Gaurav | CEO |
Nov 21 '24 |
Sale |
13.05 |
11,091 |
144,782 |
707,328 |
| Wilson Martin | General Counsel |
Nov 21 '24 |
Sale |
13.05 |
1,175 |
15,338 |
63,560 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):